Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.61 USD
+0.07 (2.76%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PSTX 2.61 +0.07(2.76%)
Will PSTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PSTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTX
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
PSTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for PSTX
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Piper Sandler Remains a Buy on Poseida Therapeutics (PSTX)
Buy Rating Justified by Poseida Therapeutics’ Promising Clinical Trial Results for P-BCMA-ALLO1 in Multiple Myeloma
Poseida Therapeutics’ P-BCMA-ALLO-1 Shows Promising Efficacy and Safety in Phase I Trials
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients